Joe Jimenez’s fund Aditum launches its 10th biotech, Celexor Bio, with autoimmune drug from Inmagene

The biotech licensing whizzes at Aditum Bio, the VC firm from ex-Novartis CEO Joe Jimenez and Mark Fishman, have created their 10th company by nabbing the rights to a preclinical autoimmune drug.

The new startup, Celexor Bio, will pay an undisclosed upfront and up to $287 million in biobucks to…
Click here to view original post